Clonazepam for the treatment of panic disorder.

  title={Clonazepam for the treatment of panic disorder.},
  author={Ant{\^o}nio Eg{\'i}dio Nardi and Sergio Machado and Leonardo Ferreira Almada and Fl{\'a}via Paes and Adriana Cardoso de Oliveira e Silva and Ricardo Jos{\'e} Marques and Roman Amrein and Rafael Christophe Freire and Roc{\'i}o Mart{\'i}n-Santos and Fiammeta Cosci and Jaime E.C. Hallak and Jos{\'e} Alexandre S. Crippa and {\'O}scar Arias-Carri{\'o}n},
  journal={Current drug targets},
  volume={14 3},
Clonazepam was initially licensed as an anti-epileptic agent, but its use in a wide variety of psychiatric conditions, including panic disorder (PD) has now been well established. This overview evaluates the current role of clonazepam alone or in combination with antidepressants and/or behavioral therapy in the treatment of PD. We review the data establishing the use of clonazepam in the treatment of PD as well as new information, particularly confirmation of longterm efficacy and safety. We… 
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class, finding that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature.
Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology
The current understanding of the potential role of glutamate neurotransmission in anxiety disorders is summarized and specific glutamate receptors that are potential targets for novel anxiety disorder treatments are highlighted.
Treatment-Resistant Panic Disorder
Panic disorder and its suboptimal treatment responses indeed significantly interfered with the individual’s functions and life qualities.
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
The results support the safety, tolerability, and anxiolytic effects of JNJ-61393215, and validate CO 2 exposure as a translational cross-species experimental model to evaluate the therapeutic potential of novel anxIOlytic drugs.
Anxiety and Related Disorders in Men
Anxiety disorders are among the most common of all psychiatric disorders and the estimated cost of anxiety disorders in the United States alone is over $42 billion per year.
Anxiety and Anxiety Disorders
The recognition and treatment of secondary and primary anxiety syndromes are discussed and the final common pathway brain dysfunction in the anxiety circuits underlies the anxiety syndrome.
A randomized, single-dose, two-sequence, two-period, crossover study to assess the bioequivalence between two formulations of clonazepam tablet in healthy subjects
Evaluating the bioequivalence between two formulations of clonazepam tablets in order to meet regulatory requirements for marketing in Colombia and other countries in Latin America found both formulations were safe and well-tolerated during the study.
Treatment Resistance in Psychiatry


Early coadministration of clonazepam with sertraline for panic disorder.
The data indicate that rapid stabilization of panic symptoms can be safely achieved with a sertraline/clonazepam combination, supporting the clinical utility of this type of regimen for facilitating early improvement ofpanic symptoms relative to sERTraline alone.
Long-term experience with clonazepam in patients with a primary diagnosis of panic disorder.
Treatment of panic disorder with the HPB clonazepam achieved and maintained a therapeutic benefit similar to that obtained with alternative pharmacologic treatments, without the development of tolerance as manifested by dose escalation or worsening of clinical status.
Combined Paroxetine and Clonazepam Treatment Strategies Compared to Paroxetine Monotherapy for Panic Disorder
Combined treatment with paroxetine and clonazepam resulted in more rapid response than with the SSRI alone, but there was no differential benefit beyond the initial few weeks of therapy.
The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder.
  • J. Susman, B. Klee
  • Psychology
    Primary care companion to the Journal of clinical psychiatry
  • 2005
High-potency benzodiaze-pines, with their proven efficacy in panic disorder exerted through control of the central nervous system excitability by a selective and potent enhancement of inhibitory gamma-aminobutyric acid-mediated neurotransmission, are also a safe and well-tolerated option for potentiation of rapid treatment response when initiating treatment with SSRIs.
Treatment of panic disorder and agoraphobia with clonazepam.
This study suggests that clonazepam, like alprazolam, may be effective in blocking panic attacks and suggests a possible common mechanism for the two drugs as high-potency benzodiazepines.
New treatment options for panic disorder: clinical trials from 2000 to 2010
A systematic review of the literature regarding the pharmacological treatment of Panic disorder in the last 10 years found that SSRIs and SNRIs were better tolerated than tricyclics and benzodiazepines as they had a low risk of dependence and overdosing complications.
Therapeutic response to benzodiazepine in panic disorder subtypes.
Clonazepam was equally effective in the treatment of the respiratory and non-respiratory subtypes of panic disorder, suggesting there is no difference in the therapeutic response between the two subtypes.
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.
  • G. Chouinard
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2004
Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome.
An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks
Long-term outcome after acute treatment with alprazolam or clonazepam for panic disorder.
The data suggest that most patients maintain benefit with long-term pharmacotherapy but that residual symptomatology may require more intensive or additional treatment strategies, and underscore the potential importance of comorbid affective and anxiety disorders as well as phobic patterns in determining long- term response to treatment.